PMC:7784830 / 8984-9152 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/7784830","sourcedb":"PMC","sourceid":"7784830","source_url":"https://www.ncbi.nlm.nih.gov/pmc/7784830","text":"Tiziana Life Sciences TZLS-501 – a monoclonal antibody and are planning to deliver it using its proprietary formulation technology, which are patent protected [51–53]","divisions":[{"label":"td","span":{"begin":0,"end":21}},{"label":"td","span":{"begin":23,"end":159}}],"tracks":[{"project":"LitCovid-sentences","denotations":[{"id":"T78","span":{"begin":0,"end":168},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"T78","pred":"source","obj":"LitCovid-sentences"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"LitCovid-sentences","color":"#cfec93","default":true}]}]}}